Bloomberg News

Takeda Rating Cut to Aa3 by Moody’s on Nycomed Acquisition

October 03, 2011

Oct. 3 (Bloomberg) -- Takeda Pharmaceutical Co. had its issuer rating cut two notches to Aa3 from Aa1 by Moody’s Investors Service on concern the acquisition of Nycomed will worsen the Japanese drugmaker’s balance sheet. The outlook for the rating is stable, Moody’s said today in a statement.

To contact the editor responsible for this story: Gearoid Reidy at

The Aging of Abercrombie & Fitch
blog comments powered by Disqus